相关实验视频

Updated: Sep 16, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

作为治疗IDH2突变AML的enasidenib:西班牙早期接入计划的多中心实践研究

Carlos Jiménez-Vicente1,2,3, Paola Beneit4, Isabel Cano-Ferri5

  • 1Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain.

Annals of hematology
|July 12, 2025
PubMed
概括

伊纳西迪尼布在IDH2-突变骨髓瘤中显示出治疗潜力,在不耐药/复发患者中提供有前途的应答率和长期存活率. 这种向治疗需要扩大获取范围,以在具有挑战性的病例中优化结果.

更多相关视频

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

564
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K